We are live on ! Find out more
VIRS

Pacer BioThreat Strategy ETF
VIRS

Delisted

VIRS was delisted on the 10th of October, 2024.

Back to rankings

4 hedge funds and large institutions have $1.12M invested in Pacer BioThreat Strategy ETF in 2023 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 2 increasing their positions, 2 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

11% more capital invested

Capital invested by funds: $1.01M → $1.12M (+$111K)

1.9% more ownership

Funds ownership: 27.47% → 29.37% (+1.9%)

0% more repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 2

33% less funds holding

Funds holding: 6 → 4 (-2)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 2

Holders
4
Holders Change
-2
Holders Change %
-33.33%
% of All Funds
0.06%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
2
Reduced
2
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Royal Bank of Canada
Royal Bank of Canada
Ontario, Canada
+$191K
2
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$77.6K

Top Sellers

Rank Fund Capital Flow
1
UBS Group
UBS Group
Switzerland
-$132K
2
Rockefeller Capital Management
Rockefeller Capital Management
New York
-$39K
3
Osaic Holdings
Osaic Holdings
Arizona
-$24.7K
4
Fidelity Investments
Fidelity Investments
Massachusetts
-$28

VIRS Hedge Fund Activity: Q1 2023 in Review

4 of the 6,283 institutional investors tracked by Wall St. Rank reported a position in Pacer BioThreat Strategy ETF (VIRS) for Q1 2023, worth a combined $1.12M — up 11% from $1.01M a quarter earlier.

Sellers outnumbered buyers: 2 funds closed out of VIRS and 0 opened new positions — a net loss of 2 holders — while 2 trimmed existing stakes and 2 added.

The largest buyer was Royal Bank of Canada, adding an estimated $191K. The largest seller was UBS Group, cutting an estimated $132K.

  • 4 institutional investors held Pacer BioThreat Strategy ETF (VIRS) as of Q1 2023, down from 6 in Q4 2022.
  • Funds reported $1.12M of Pacer BioThreat Strategy ETF stock for Q1 2023, up 11% quarter-over-quarter.
  • 0 funds opened new Pacer BioThreat Strategy ETF positions in Q1 2023 and 2 closed out, a net change of -2 holders.
  • The largest Pacer BioThreat Strategy ETF buyer in Q1 2023 was Royal Bank of Canada, an estimated $191K added.
  • The largest Pacer BioThreat Strategy ETF seller in Q1 2023 was UBS Group, an estimated $132K sold.

Based on aggregated 13F filings for Q1 2023.